Phase II study of non-myeloablative allogeneic bone marrow transplantation for B-cell lymphoma with post-transplantation rituximab and donor selection based first on non-HLA factors

Lignende værker

• Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: a Retrospective Cohort Study
  af: Paul, Suman, et al.
  Udgivet: (2020)
• Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide
  af: McCurdy, Shannon R., et al.
  Udgivet: (2018)
• Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation
  af: Kasamon, Yvette L., et al.
  Udgivet: (2018)
• Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide
  af: Lombardi, Lindsey R., et al.
  Udgivet: (2015)
• Absence of posttransplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using posttransplantation cyclophosphamide as graft-versus-host disease prophylaxis
  af: Kanakry, Jennifer A., et al.
  Udgivet: (2013)